{"id":"tiv-followed-by-laiv","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site soreness or swelling"},{"rate":null,"effect":"Nasal congestion or runny nose"},{"rate":null,"effect":"Fever or chills"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This sequential vaccination strategy uses an inactivated vaccine first to establish systemic immunity, then administers a live attenuated vaccine to enhance mucosal immunity and broaden the immune response. The combination approach aims to provide superior protection against multiple influenza strains compared to either vaccine alone.","oneSentence":"TIV (inactivated influenza vaccine) primes the immune system, followed by LAIV (live attenuated influenza vaccine) to boost mucosal and systemic immunity against influenza.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:12:58.892Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT05921448","phase":"EARLY_PHASE1","title":"Vaccine Pandemic Preparedness Through Airway Immunology Characterization","status":"ACTIVE_NOT_RECRUITING","sponsor":"Copenhagen Respiratory Research","startDate":"2025-05-19","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT02597647","phase":"PHASE1","title":"Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-02","conditions":"Influenza","enrollment":17},{"nctId":"NCT06841913","phase":"PHASE4","title":"Woodsmoke Exposure, Influenza Infection, and Nasal Immunity","status":"SUSPENDED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-10-01","conditions":"Smoke Exposure, Influenza","enrollment":112},{"nctId":"NCT03735147","phase":"PHASE4","title":"Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2018-10-23","conditions":"Influenza Vaccines","enrollment":12},{"nctId":"NCT03300050","phase":"PHASE1","title":"Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2017-10-10","conditions":"Influenza, Vaccine","enrollment":65},{"nctId":"NCT03453801","phase":"PHASE1","title":"The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection","status":"COMPLETED","sponsor":"Stanford University","startDate":"2014-09-30","conditions":"Influenza, Healthy","enrollment":80},{"nctId":"NCT02251288","phase":"PHASE1","title":"A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-05-18","conditions":"Avian Influenza, Immunisation","enrollment":62},{"nctId":"NCT02549365","phase":"PHASE4","title":"Efficacy & Safety of Nasal Influenza Immunisation in Children","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-10","conditions":"Influenza Vaccines Efficacy and Safety","enrollment":276},{"nctId":"NCT02153671","phase":"PHASE2","title":"Immunogenicity of H5N1 Vaccine Following H5N2","status":"COMPLETED","sponsor":"PATH","startDate":"2014-05","conditions":"Influenza Vaccine","enrollment":43},{"nctId":"NCT03502291","phase":"PHASE4","title":"The Effect of Live Attenuated Inactivated Influenza Vaccine on Experimental Human Pneumococcal Carriage Study","status":"COMPLETED","sponsor":"Liverpool University Hospitals NHS Foundation Trust","startDate":"2015-08","conditions":"Pneumonia, Influenza, Human","enrollment":324},{"nctId":"NCT01246999","phase":"PHASE4","title":"Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2010-10","conditions":"Influenza","enrollment":34},{"nctId":"NCT02266992","phase":"PHASE2","title":"Exploring Novel Mechanisms of Vaccine Failure LAIV Pilot Study","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2014-09","conditions":"Acquired Immune Deficiency Syndrome Virus","enrollment":28},{"nctId":"NCT01534468","phase":"PHASE1","title":"Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-03","conditions":"Influenza A Subtype H7N7 Infection","enrollment":45},{"nctId":"NCT00617110","phase":"NA","title":"Effects of Diesel Exhaust Followed by Administration of Nasal Spray Flu Vaccine on Individuals With & Without Allergies","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2008-01","conditions":"Allergic Rhinitis","enrollment":54},{"nctId":"NCT02229357","phase":"PHASE2","title":"Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2014-06","conditions":"Avian Influenza","enrollment":60},{"nctId":"NCT01194297","phase":"PHASE4","title":"Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants","status":"TERMINATED","sponsor":"University of Rochester","startDate":"2010-08","conditions":"Influenza","enrollment":3},{"nctId":"NCT01044095","phase":"NA","title":"Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus","status":"COMPLETED","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2009-11","conditions":"Influenza","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Seasonal Influenza Vaccines"],"phase":"marketed","status":"active","brandName":"TIV followed by LAIV","genericName":"TIV followed by LAIV","companyName":"University of Rochester","companyId":"university-of-rochester","modality":"Biologic","firstApprovalDate":"","aiSummary":"TIV (inactivated influenza vaccine) primes the immune system, followed by LAIV (live attenuated influenza vaccine) to boost mucosal and systemic immunity against influenza. Used for Influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}